secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sigyn Therapeutics, Inc. (SIGY)
CIK:        0001642159
Form:       8-K
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0001493152-25-009462
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO
--------------------------------------------------------------------------------

- CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.
- CEO James Joyce will serve as interim CFO following DeCiccio's retirement.
- Sigyn entered into a Consulting Agreement with DeCiccio for continued financial support services.
- CEO released a letter on March 5, 2025, outlining Sigyn Therapy's potential against emerging viral threats.
- Sigyn Therapy targets viruses, bacterial toxins, inflammatory cytokines, and has a clinical strategy for ESRD patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/0001493152-25-009462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer